Polymyalgia Rheumatica

Posts Tagged ‘risk’

(Vocus/PRWEB) February 09, 2011

For Immediate Releasemay be used in whole or part with attribution. Media inquiries welcome.

Read the rest of this entry »

Cerebrovasc Dis 2011;32:497–503 (DOI:10.1159/000332031) (Source: Cerebrovascular Diseases)
MedWorm: Polymyalgia Rheumatica

Authors: Kristinsson SY, Landgren O, Samuelsson J, Björkholm M, Goldin LR
The causes of myeloproliferative neoplasm (MPN) are unknown. We conducted a large population-based study including 11,039 MPN patients and 43,550 matched controls with the aim to assess the associations between a personal history of a broad span of autoimmune diseases and subsequent risk of MPN. We found a prior history of any autoimmune disease to be associated with a significantly increased risk of MPNs (odds ratio (OR)=1.2; 95% confidence interval (CI) 1.0-1.3; p= 0.021). Specifically, we found an increased risk of MPNs associated with a prior immune thrombocytopenic purpura (2.9; 1.7-7.2), Crohn’s disease (1.8; 1.1-3.0), polymyalgia rheumatica (1.7; 1.2-2.5), giant cell arteritis (5.9; 2.4-14.4), Reiter’…

Conclusions
Personal history of certain immune-related and/or infectious conditions was strongly associated with increased risk of LPL-WM. The association of both personal and family history of Sjögren syndrome and autoimmune hemolytic anemia with risk of LPL-WM indicates the potential for shared susceptibility for these conditions. (Source: JNCI)
MedWorm: Polymyalgia Rheumatica

Conclusions. Patients hospitalized for PMR and GCA had a marginally increased risk of cancer, with the highest risk noted for the first year after hospitalization. However, for specific cancers, such as skin cancer and leukaemia, the increases were still significant for patients diagnosed later than 1 year after hospitalization, suggesting that these could be true associations, but the mechanisms remain to be established. (Source: Rheumatology)
MedWorm: Polymyalgia Rheumatica

Conclusion: Patients with high BMI ([ge] 25 kg/m2) are not more likely to develop PMR. BMI did not influence the duration of glucocorticoid therapy or the occurrence of GCA in patients with PMR. (Source: APLAR Journal of Rheumatology)
MedWorm: Polymyalgia Rheumatica

CONCLUSION: IL2RA rs2104286 polymorphism does not appear to be a genetic risk factor for susceptibility to biopsy-proven GCA. Also, this polymorphism does not seem to be implicated in the clinical expression of this vasculitis.
PMID: 20810507 [PubMed - as supplied by publisher] (Source: J Rheumatol)
MedWorm: Polymyalgia Rheumatica

CONCLUSION: IL2RA rs2104286 polymorphism does not appear to be a genetic risk factor for susceptibility to biopsy-proven GCA. Also, this polymorphism does not seem to be implicated in the clinical expression of this vasculitis.
PMID: 20810507 [PubMed - as supplied by publisher] (Source: J Rheumatol)
MedWorm: Polymyalgia Rheumatica

Conclusion:One in 12 women and 1 in 20 men will develop inflammatory autoimmune rheumatic disease during their lifetime. These results can serve as useful guides in counseling patients regarding their lifetime risk of these conditions and have important implications for disease awareness campaigns. (Source: Arthritis and Rheumatism)
MedWorm: Polymyalgia Rheumatica

Conclusion:One in 12 women and 1 in 20 men will develop inflammatory autoimmune rheumatic disease during their lifetime. These results can serve as useful guides in counseling patients regarding their lifetime risk of these conditions and have important implications for disease awareness campaigns. (Source: Arthritis and Rheumatism)